Company news

Invion Ltd. news in 2025

Invion Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Hanlim & Korean Government Fund Pathway to Clinical Trial

December 22, 2025

Invion Secures Expanded Photosoft Global Exclusive License

December 2, 2025

Appendix 4C and Quarterly Activities Report - September 2025

October 30, 2025

Funded Collaboration Agreement with Protect Animal Health

October 20, 2025

Repayment of Lind Facility with Successful Capital Raise

October 9, 2025

Response to ASX Aware Letter

August 27, 2025

Appendix 4E and Annual Report

August 27, 2025

Response to ASX Price Query

August 20, 2025

Orphan Drug Designation Granted by U.S. FDA For Anal Cancer

August 20, 2025

Appendix 4C and Quarterly Activities Report - June 2025

July 31, 2025

Security Class Reinstatement to Quotation

July 17, 2025

Security Class Suspension from Quotation

July 10, 2025

Underwritten Loyalty Option Entitlement Offer Prospectus

June 23, 2025

EQR Progresses Regional Tungsten Hub Strategy

June 13, 2025

Loyalty Option Entitlement Offer

June 13, 2025

Encouraging SRC Findings on Ph I/II Skin Cancer Trial

May 28, 2025

Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial

May 1, 2025

Appendix 4C and Quarterly Activities Report - March 2025

April 30, 2025

Share Purchase Agreement Termination and Tranche Repayment

March 4, 2025

Completion Of Placement to Accelerate Clinical Programs

March 4, 2025

Oesophageal Cancer Collaboration and Funding Agreement

February 25, 2025

Activities Report and Appendix 4C

January 30, 2025

Decks in 2025